← Back

Guangzhou Improve Med Instrument

Improve Medical Instruments Co., Ltd. provides technologies, products, and services for clinical laboratories and clinical nursing in China and internationally. Its offerings include clinical laboratory products such as feces and thrombosis viscoelastic analysis systems, automatic biosafety decappers, and the Q-VELOX intelligent molecular diagnostic workstation. The company also supplies specimen processing equipment under the IMPROVACUTER brand, including evacuated blood collection systems, tubes, multi-sample needles, blood collection sets, tourniquets, urine collection systems, and holders, as well as IMPROMINI capillary blood collection systems, IMPROSWAB microbiological transportation systems, IMPRONURSE infusion and syringe pumps, LONGX urine analysis systems, in-vitro diagnostic reagents, IMPROSAFE safety blood collection needles, IMPROVE sharps containers, and liquid biopsy pre-analytical systems. In addition, it offers clinical nursing products such as automatic, handheld, pulsewave, and smart wireless blood pressure monitors, and intelligent management solutions including blood collection tube preparation systems, graphic user interfaces, intelligent sorters, multi-function blood collection tables, intelligent queue systems, urine collection tube preparation systems, automatic tube packer systems, consumable labels, CryoMax vials, and liquid nitrogen freezing storage boxes. The company was formerly known as Guangzhou Improve Medical Instruments Co., Ltd. and changed its name to Improve Medical Instruments Co., Ltd. in December 2021. Founded in 1996, it is headquartered in Guangzhou, China.

Price · split & dividend adjusted
News & notes moving 300030.CS
300030.CS2

Improve Medical's 2026 interim net profit reached 30.8149 million yuan, up 101.85% year on year

Improve Medical released its 2026 interim report, with net profit attributable to the parent company of 30.8149 million yuan, an increase of 15.5484 million yuan compared with the same period last year, up 101.85% year on year, achieving growth for two consecutive years. The company's total operating revenue was 215 million yuan, and net cash inflow from operating activities was 56.7587 million yuan, up 231.77% year on year. The latest asset-liability ratio was 31.64%, down 9.69 percentage points from the same period last year; the gross margin was 47.70%, up 6.33 percentage points year on year, achieving growth for three consecutive years. Diluted earnings per share were 0.10 yuan, up 100% year on year.
Jiemian·34dRead more →